Background--Drug-eluting stents (DESs) and bare metal stents (BMSs) are both recommended to improve coronary revascularization and to treat coronary artery disease in patients with chronic kidney disease (CKD). However, the potential superiority of DESs over BMSs for reducing the incidence of long-term major adverse cardiovascular events and mortality in CKD patients has not been established, and the results remain controversial. We aimed to systematically assess and quantify the total weight of evidence regarding the use of DESs versus BMSs in CKD patients.
C hronic kidney disease (CKD) is a worldwide public health concern 1,2 and is frequently accompanied by cardiovascular diseases, including coronary artery disease. 3, 4 Cardiovascular diseases are the leading cause of morbidity and mortality in CKD patients. CKD is a well-recognized risk factor of premature atherosclerosis. 5, 6 This disease promotes hypertension and dyslipidemia, which-together with diabetes mellitus (a major cause of renal failure)-are important risk factors of endothelial dysfunction and atherosclerosis progression. 7 In addition to these common risk factors, the accelerated atherosclerosis in CKD patients is also associated with several uremia-related risk factors, such as inflammation, oxidative stress, hyperhomocysteinemia, and immunosuppressant use. Finally, the increase in calcification promoters and the reduction in calcification inhibitors favor metastatic vascular calcification, another important risk factor of vascular injury in CKD patients. 8 CKD patients frequently require coronary revascularization, which poses technical challenges due to the extensiveness and calcifiability of coronary artery disease. Accordingly, percutaneous coronary intervention is expected to reduce procedural success. 9 CKD is an independent predictor of worse outcomes following percutaneous coronary intervention compared with preserved kidney function. [10] [11] [12] [13] Conflicting results of efficacy and safety between drug-eluting stents (DESs) and bare metal stents (BMSs) have been reported. Several post hoc analyses and registries have compared the efficacy of DESs and BMSs in this high-risk population. Recent randomized controlled trials (RCTs) and observational studies (OSs) suggest that the introduction of DESs versus BMSs may provide favorable outcomes. [14] [15] [16] [17] The benefit of DESs, however, is limited to short-term outcomes because of extremely late stent thrombosis in DESs, especially in first-generation DESs in populations with CKD 18 or high bleeding risk. 19 In addition, no significant difference in long-term outcomes among first-generation DESs, second-generation DESs, and BMSs 20 was found. Moreover, these studies included small population sizes and presented conflicting findings. A broad range of kidney function should be included because CKD patients are susceptible to both bleeding incidents and in-stent thrombosis. 13 The potential superiority of DESs over BMSs for reducing the incidence of long-term major adverse cardiovascular events (MACE) and mortality in CKD patients has not been established.
To assess the clinical outcomes of DESs versus BMSs in CKD patients, we performed a meta-analysis of the existing and up-to-date studies.
Methods Search Strategy and Selection Criteria
In this systematic review and conventional meta-analysis, the search strategy was developed and the search performed by 2 experienced medical investigators (R.L. and Y.Z.). They searched for RCTs and OSs published until May 20, 2016 (date of the last search) in PubMed, Ovid Embase, Web of Science, and the Cochrane Central Register of Controlled Trials. Keywords included coronary artery disease, chronic kidney disease, end-stage renal disease, dialysis, drug-eluting stents, bare metal stents, and stents. Subsequently, another investigator (F.T.) manually searched the references cited by relevant published reviews. We attempted to contact the authors to clarify published data if necessary.
Inclusion and Exclusion Criteria
Inclusion criteria were (1) RCT, cohort study, or OS and (2) comparison of clinical outcomes between DESs and BMSs in CKD patients (regardless of CKD stage or dialysis type). Exclusion criteria were comparison of different types of DESs; kidney transplantation; and case report, review, comment, editorial, letter, quasiexperiment, or unpublished study. When >1 study from the same team or institution met the inclusion criteria, only the study with the largest sample size or the latest publication was included.
Data Extraction
We selected studies and extracted data according to a standard Cochrane protocol. 21 
Quality Assessment
The quality of each study was independently assessed by 2 investigators (R.L. and Y.Z.). The risk of bias of each RCT was evaluated with the Cochrane Collaboration's risk of bias tool containing 6 domains (sequence generation; allocation concealment; blindness of participants, personnel, and outcome assessors; incomplete outcome data; selective outcome reporting; other sources of bias), with 3 levels for each domain (low, unclear, or high bias). The summary risk of bias was determined to be high if at least 1 domain was assessed as high risk of bias and low only if all domains were judged as low risk of bias. 22 The Newcastle-Ottawa Scale (NOS) consists of 3 quality parameters for cohort studies, namely, selection, comparability, and outcome, which were assigned a maximum of 4, 2, and 3 stars, respectively; therefore, 9 stars reflected the highest quality. A study with >6 stars was considered high quality. 23 Any discrepancy was resolved through a joint 
Data Synthesis
Dichotomous outcomes were pooled using odd ratios (ORs) with 95% CIs. Heterogeneity among studies was assessed using the I 2 statistic, with I 2 <25% as minimal, I 2 <50% as moderate, and I 2 ≥50% as substantial. All analyses were performed using the random-effects model regardless of heterogeneity testing. Publication bias was examined through (1) visual interpretation of funnel plot asymmetry, with the estimated effects plotted against standard errors; (2) Begg's adjusted rank correlation test; and (3) Egger's regression asymmetry test. If publication bias was found, Duval and Tweedie's trim-and-fill method was performed.
Sensitivity and meta-regression analyses were conducted to assess whether heterogeneity could be attributed to any measurable source. Subgroup analyses for MACE and allcause mortality against several variables were performed to identify possible causes of heterogeneity and to assess the robustness of the relationships. These variables included study design (RCT, prospective cohort study, and retrospective cohort study), number of patients (<500 or ≥500 total patients), ethnicity (white and Asian), CKD stage (dialysis and nondialysis), mean duration of follow-up (<12, 12-36, and ≥36 months), percentage of patients with diabetes mellitus (<25%, 25-50%, and ≥50%), and adjusted or propensity score matching (yes and no). All analyses were performed using Stata 12.0 (StataCorp) and Review Manager 5.3.5 (Cochrane Collaboration). P<0.05 was considered statistically significant, except for the publication bias test (P<0.10). A total of 4311 potentially relevant articles were initially identified and screened. Among these articles, 81 were retrieved for detailed evaluation. In total, 38 articles met the inclusion criteria (Figure 1 ), including 6 RCTs (1 real RCT, 15 
Quality Assessment
Methodological quality assessments showed that the 32 OSs had an average NOS score of 8.125 and were all of high quality (NOS score ≥7) except 1 (Table S1 ). 
Effect of DESs Versus BMSs on MACE and All-Cause Mortality
In 4 RCTs (including analysis of RCT), [25] [26] [27] [28] the association between the use of DESs or BMSs and the incidence of MACE was insignificant (pooled OR 0.78; 95% CI 0.53-1.14; P=0.201) in the random-effects model without heterogeneity (Figure 2 ). In 20 OSs, ¶ the association was significant (a 25% reduction in the incidence of MACE; pooled OR 0.75; 95% CI 0.63-0.89; P=0.001) in the random-effects model with substantial heterogeneity (I 2 =82.4%; P<0.001) (Figure 2 ). In 5 prospective cohort studies, 39 ,47,49,50,52 the association was significant with a reduced incidence of MACE (pooled OR, 0.56; 95% CI, 0.33-0.96; P=0.036) in the random-effects model with substantial heterogeneity (I 2 =89.5%; P<0.001) (Figure 3 ). In 15 retrospective cohort studies, # the association was also significant (pooled OR 0.81; 95% CI, 0.66-0.99; P=0.045) with substantial heterogeneity (I 2 =70.6%; P<0.001) (Figure 3 ). Subanalyses showed that the association between DESs or BMSs and MACE was significant for small sample sizes, white ethnicity, nondialysis status, moderate duration of follow-up, high percentage of patients with diabetes mellitus, and adjusted or propensity score matching (Figure 3 ). Metaregressions were conducted to determine whether the inconsistency could be explained by any of the heterogeneity sources; however, no significant factor that contributed to heterogeneity was found (all P>0.1), indicating that the between-study heterogeneity was not well explained by any of the characteristics tested.
The association between DESs or BMSs and all-cause mortality was significant (pooled OR 0.81, 95% CI 0.73-0.90; P<0.001) (Figure 4 ) in the random-effects model with substantial heterogeneity in the magnitude of effect across all included studies (I 2 =78.1%; P<0.001). The subsequent subgroup analysis ( Figure 5 ) revealed greater effects for retrospective cohort studies, Asian ethnicity, moderate duration of follow-up, moderate and high percentages of patients with diabetes mellitus, and adjusted or propensity score matching, which was attenuated to some extent in RCTs and prospective cohort studies. The funnel plots showed no apparent systematic bias ( Figure 6 ) (Begg's test, P=0.941), but Egger's tests revealed significant publication bias (P=0.004) in the analysis of MACE. When the influence of potential publication bias was investigated using the trim-and-fill method, the potential missing data were not replaced, and the findings were generally similar with a decreased risk of MACE in the patients with percutaneous coronary intervention (pooled OR 0.62; 95% CI 0.52-0.72; P<0.001). No substantial systematic bias was found from the funnel plots (Figure 7) in the analysis of allcause mortality (Begg's test, P=0.61; Egger's test, P=0.271).
Effect of DESs Versus BMSs on MI, TLR, and TVR
The use of DESs versus BMSs produced a 20% significant reduction in MI (OR 0.80; 95% CI 0.67-0.95; P<0.001) ( Figure S1 ), with no substantial heterogeneity (I 2 =32.9%;
P=0.082). It had a significant effect on TLR (OR 0.69; 95% CI 0.52-0.92; P=0.014) ( Figure S2 ) and TVR (OR 0.55; 95% CI 0.42-0.73; P<0.001) ( Figure S3 ). Substantial heterogeneity existed in the results of TLR (I 2 =58.0%, P=0.003) and TVR (I 2 =64.1%, P<0.001). Metaregressions were also used to explore whether the inconsistency could be explained by any of the heterogeneity sources; however, no significant factor that contributed to heterogeneity was found (all P>0.1).
Discussion
The meta-analysis demonstrated that the use of DESs versus BMSs in CKD patients was significantly associated with reductions in the incidence of MACE, all-cause mortality, MI, TLR, and TVR. The use of DESs versus BMSs showed superior efficacy in reducing the rate of MACE in the CKD population primarily by reducing TLR. Our survival result is similar to that of a present metaanalysis that shows use of DESs versus BMSs significantly reduces mortality rate in OSs but not in RCTs. 53 Several possible explanations may exist as to why the mortality rate was significantly reduced with the use of DESs compared with BMSs in the OSs, with an attenuated effect in the RCTs. Proponents of observational data cite added generalizability and the fact that more patients have been studied in the observational registries compared with the RCTs, providing much more power to detect differences in low-frequency safety events. Conversely, observational analyses are subject to confounding with regard to the nonrandomized choice of either DESs or BMSs. Multivariable adjustment can be used to mitigate the effect of measured confounders on the effect estimate for DESs versus BMSs within individual studies. As such, the observed attenuation of the overall summary estimate of mortality favoring DESs compared with BMSs in the adjusted versus unadjusted analyses was notable. Consequently, this survival benefit of DESs versus BMSs should be interpreted with caution because of the nonrandomized nature of the data sources and the heterogeneity across studies. The mortality benefit of DESs versus BMSs should be verified in large RCTs. Significant differences were found in the incidence rates of MI, TLR, and TVR between DES-and BMS-treated patients. Realworld patients with CKD, particularly those with end-stage renal disease on dialysis, are at high risk of serious bleeding events due to chronic heparin exposure, uremia-induced platelet dysfunction, and concomitant use of anticoagulants. [54] [55] [56] Such patients are also more likely to discontinue clopidogrel or other antiplatelet agents prematurely. 57 The discontinuation of these agents leads to in-stent thrombosis and subsequent MI. 58 Moreover, data regarding medication, especially antiplatelet regimens, are limited, but the use of DESs typically follows a dual antiplatelet regimen that can increase the mortality rate in patients with coronary artery disease. 59 Meanwhile, the difference in MI definitions may change the end point measurement and curative effect comparison. MI is defined as hospitalization with a principal diagnosis of MI 45 or as an elevation of cardiac enzymes and/or the development of new pathological Q wave on electrocardiogram. 22, 30 The benefit of decreased TLR and TVR from the use of DESs is not clearly elucidated and may be affected by multiple factors, such as longer use of antiplatelet agents (eg, clopidogrel) and differences in follow-up care. As expected, our systematic review and meta-analysis showed the heterogeneity in ORs among OSs. This heterogeneity may be attributed to the differences in study designs, demographics, and statistical approaches. Despite the strict criteria used, the included studies represented a comprehensive attempt to cull published and unpublished literature reports in this field; therefore, we used the summary-level estimates of individual study effects. Meanwhile, conventional statistical approaches used in OSs were not sufficiently powerful to address the effects of unmeasured confounders on the overall effect estimate. We attempted to investigate the heterogeneity sources through various sensitivity analyses and metaregressions but did not find any simple explanation or way that accounted for the heterogeneity.
This review and meta-analysis has several strengths, including the broad search strategy (standard Cochrane protocol) and large sample size. It also has several shortcomings. First, only 1 real RCT was included, but the patient cohort in this trial was excessively selected. Its 1-year death rate of only 3.7% was much lower than the annual death rates for patients with CKD and coronary heart disease overall. Second, we could not identify unpublished reports, and that might bias our results. Significant heterogeneity was noted among OSs. Meanwhile, the forms of DESs differed substantially across trials because second-generation DESs showed survival superiority over first-generation DESs. 60 Moreover, Egger's tests showed a potential publication bias for MACE that is difficult to ascertain. Our findings might have overestimated the true effect if we missed some insignificant studies. In summary, this meta-analysis provides substantial evidence that DESs significantly decreased the occurrence of MACE, all-cause mortality, MI, TLR, and TVR in CKD patients. DESs, particularly second-generation DESs for percutaneous coronary intervention, appeared to be safe and efficient in CKD patients. Nevertheless, the true effect of DESs versus BMSs should be confirmed by further RCTs.
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